Technetium Tc-99m pyrophosphate for cerebrospinal fluid leaks: radiopharmaceutical considerations.

OBJECTIVE To confirm the anticipated image quality and absence of adverse reactions in patients undergoing clinical practice cerebrospinal fluid (CSF) leak imaging procedures using technetium Tc-99m pyrophosphate (PYP). METHODS Following the recent discontinuation of preservative-free calcium trisodium diethylene triamine pentaacetic acid kits, PYP was selected as a suitable alternative for CSF leak imaging procedures. Procedures were established for its preparation and dispensing, paying special attention to safety considerations, and its use in clinical practice was implemented. Medical records, including images, were reviewed for the first 15 patients undergoing clinical practice CSF imaging procedures using Tc-99m PYP to confirm anticipated image quality and absence of adverse effects. RESULTS Review of CSF leak imaging procedures using Tc-99m PYP in 15 patients showed images to be of uniformly high quality. The vast majority of injected radiopharmaceutical remained in the CSF throughout the duration of the imaging procedure, allowing visualization of CSF leaks. Only a small amount of Tc-99m PYP diffused into the blood with resultant uptake on the skeleton and excretion into the urine, which did not interfere with image interpretation. No adverse reactions were noted in any of the patients. CONCLUSION With proper attention to safety considerations, Tc-99m PYP is a safe and effective alternative for performing CSF leak imaging procedures.

[1]  V. Ghalaut,et al.  Case series: CSF LDH, proteins and electrolyte levels in patients of acute lymphocytic leukemia. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[2]  J. Hatton,et al.  Intracerebroventricular Administration of Drugs , 2009, Pharmacotherapy.

[3]  M. Graham,et al.  Radionuclide Cisternography in Detecting Cerebrospinal Fluid Leak in Spontaneous Intracranial Hypotension: A Series of Four Case Reports , 2009, Clinical nuclear medicine.

[4]  J. Ponto.  Special safety considerations in preparation of technetium Tc-99m DTPA for cerebrospinal fluid-related imaging procedures. , 2008, Journal of the American Pharmacists Association : JAPhA.

[5]  T. Wong,et al.  Comparison of Tc99m-DTPA and indium-111 DTPA studies of baclofen pump function. , 2004, Clinical nuclear medicine.

[6]  R. Schlosser,et al.  Nasal Cerebrospinal Fluid Leaks: Critical Review and Surgical Considerations , 2004, The Laryngoscope.

[7]  L. Basauri,et al.  Electrolyte levels in the CSF of children with nontumoral hydrocephalus , 1985, Child's Nervous System.

[8]  B. Mokri.  Spontaneous intracranial hypotension , 2001, Current neurology and neuroscience reports.

[9]  L. Pierot,et al.  Radionuclide cisternography in spontaneous intracranial hypotension. , 1998, Clinical nuclear medicine.

[10]  S. Renowden,et al.  Spontaneous intracranial hypotension. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[11]  M. Graham,et al.  Benefit of tomography in the scintigraphic localization of cerebrospinal fluid leak. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. El‐Yazigi,et al.  Concentrations of chromium, cesium, and tin in cerebrospinal fluid of patients with brain neoplasms, leukemia or other noncerebral malignancies, and neurological diseases. , 1988, Clinical chemistry.

[13]  Ponto Ja.  Intrathecal administration of radiopharmaceuticals for cisternography. , 1987 .

[14]  P. J. Robbins.  Chromatography of technetium-99m radiopharmaceuticals : a practical guide , 1984 .

[15]  K. Karstens,et al.  Magnesium and inorganic phosphate content in CSF related to blood-brain barrier function in neurological disease , 1979, Journal of the Neurological Sciences.

[16]  M. Billinghurst,et al.  Radiation decomposition of technetium-99m radiopharmaceuticals. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.